The designation entitles Moleculin to receive a transferrable Priority Review Voucher (PRV) upon New Drug Approval (NDA)... Dec 03
Moleculin declares new antiviral drug candidates demonstrate in vitro activity against HIV. Also shows activity in Zika and Dengue Fever ... Oct 06
Sterling Signs Deal to contract manufacture COVID-19 Drug Candidate for Moleculin ... Jul 28
-Advertisements-